Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19) (5 May 2020)

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 (1 May 2020)

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 (1 May 2020)

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 (1 May 2020)

Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 (17 April 2020)

COVID-19, ACE2, and the Cardiovascular Consequences. Andrew M. South, Debra I. Diz, and Mark C. Chappell (31 March 2020)

Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection. David S. Fedson, Steven M. Opal and Ole Martin Rordam (20 March 2020)

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Markus Hoffmann, Hannah Kleine Weber, Simon Schroeder, et al. (5 March 2020)

Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target (3 March 2020)

Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics (25 February 2020)

ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism (7 February 2020)

Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 aftervascular balloon injury in rats (18 June 2013)

Renin–angiotensin system in human coronavirus pathogenesis (1 March 2010)

Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures (1 February 2010)

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury (10 July 2005)